Skip to main content
Dhan
Search
Search
Loading...
Scanning the Markets...

Home

Symbiotec Pharmalab IPO GMP Day 4: GMP ₹265 (26.82%) & 75.08x Subscribed


Symbiotec Pharmalab IPO GMP Day 4: GMP ₹265 (26.82%) & 75.08x Subscribed

This public issue of ₹1,757 crore, comprises a fresh issue of ₹150 crore and an offer for sale (OFS) of ₹1,607 crore by the existing promoters and shareholders.

Fact Checked
Ridhima Gandhi
Ridhima Gandhi
|Aug 27, 2026, 06:08 PM
TelegramXLinkedIn
Add as a preferred source on Google
Symbiotec Pharmalab IPO GMP Day 4: GMP ₹265 (26.82%) & 75.08x Subscribed


Key takeaways:

  • Symbiotec Pharmalab is raising ₹1,757 crore through a mix of a fresh issue (₹150 crore) and an OFS (₹1,607 crore).
  • The price band is fixed at ₹938 to ₹988 per share, with a minimum retail investment of ₹14,820 for 15 shares.
  • The IPO had a four-day bidding period, as opposed to the usual three-day period, and the bidding officially closed today, August 27, 2026.
  • The issue saw a massive response on the last day of bidding, with an overall subscription of 75.08 times.
  • The current GMP is ₹265, indicating an estimated listing price of ₹1,253, and a potential listing premium of approximately 26.82%.
  • The company is a global leader in corticosteroid and steroidal hormone APIs with several international regulatory approvals.

Symbiotec Pharmalab Limited has officially closed its extended four-day bidding window for its IPO today. The company is a market leader in corticosteroid and steroidal hormone APIs. The IPO on the last day witnessed a considerable increase in demand after a steady start in the previous three days.

At the close of its bidding window, it had a total subscription of 75.08 times and a GMP of ₹265, which could lead to a listing gain of about 26.82%.

The company plans to use ₹112.50 crore of the fresh proceeds to prepay and repay outstanding borrowings, which will strengthen its balance sheet and support further growth. Here we will discuss in detail the last-day bidding of the Symbiotec Pharmalab IPO.

Important dates of Symbiotec Pharmalab IPO

The Symbiotec Pharmalab Limited IPO officially closed its extended four-day bidding window today, August 27, 2026. Bidding for the Symbiotec Pharmalab IPO began on Monday, August 24, 2026. The allotment of shares is likely to be finalised on Friday, August 28, 2026. The company will initiate refunds and unblock bank mandates for investors who have not been allotted shares on Monday, August 31, 2026.

The successful bidders will get the equity shares credited to their demat accounts on the same day. The company plans to list on the stock exchanges on Tuesday, September 1, 2026, with a tentative listing on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE).

The stock price range is set at ₹938 to ₹988 per share. A minimum subscription is 1 lot, which consists of 15 shares and requires an investment of ₹14,820 from retail investors. The book-running lead managers for the issue are JM Financial, Avendus Capital, Motilal Oswal Investment Advisors and Nomura Financial, and MUFG Intime India is the official registrar.

About Symbiotec Pharmalab

Incorporated in 2002, Symbiotec Pharmalab has grown into a research-driven pharmaceutical and biotechnology powerhouse. The company focuses on the development and production of complex active pharmaceutical ingredients (APIs), nutritional ingredients and special biotechnology-based products for the domestic and international markets.

Symbiotec is a global leader in the production of corticosteroid and steroidal hormone APIs by volume, with a wide range of APIs for highly regulated pharmaceutical markets. In addition to its own product portfolio, the company offers in-demand contract development and manufacturing (CDMO) services to pharmaceutical and nutraceutical customers worldwide.

​The company's financial performance has been highly impressive in recent years. Symbiotec Pharmalab's total income in FY26 was ₹872.26 crore, compared to ₹755.98 crore in FY25. Further, its profit after tax (PAT) has seen a healthy increase, rising to ₹109.90 crore in FY26 from ₹96.79 crore in the previous financial year.

Last-day subscription status and GMP

At the end of bidding on Day 4 (August 27, 2026), the total subscription of the Symbiotec Pharmalab IPO soared to 75.08 times. The late momentum was largely propelled by Non-Institutional Investors (NIIs) and Qualified Institutional Buyers (QIBs) who finally joined the IPO issue in large numbers.

The Non-Institutional Investors (NIIs) segment oversubscribed its quota by a whopping 77.56 times.

Qualified Institutional Buyers (QIBs) investments rushed in during the last few hours, and the QIB portion was booked 181.20 times. Retail Individual Investors (RIIs) also participated with great enthusiasm, booking their quota 13.69 times. In addition, the employee reserved portion was oversubscribed by 16.32 times.

The unlisted Grey Market sentiment remained highly positive. Symbiotec Pharmalab's Grey Market Premium (GMP) was ₹265 on the last day. At the upper price band of ₹988, this current GMP suggests a listing price of ₹1253, which could deliver a healthy listing gain of 26.82% for the successful allottees.

This phenomenal retail and institutional participation is attributed to the company's market leadership in high-barrier steroidal APIs, strong customer relationships, and its attractive valuation compared to its listed peers. All eyes are now on September 1, 2026, to see how Symbiotec Pharmalab's shares make their official debut on the Indian stock exchanges.


fuzz
ipo banner

Read More on Ipo

Pre-apply for Upcoming IPOs